
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Case Scenario: A 52-year old male with mRCC
February 2018
